AstraZeneca PLC (AZN)vsEmpro Group Inc. Ordinary shares (EMPG)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
EMPG
Empro Group Inc. Ordinary shares
$17.36
0.00%
HEALTHCARE · Cap: $143.05M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 1070861% more annual revenue ($58.74B vs $5.48M). AZN leads profitability with a 17.4% profit margin vs 13.7%. AZN trades at a lower P/E of 27.9x. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
EMPG
Hold47
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Intrinsic value data unavailable for EMPG.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Every $100 of equity generates 66 in profit
Strong operational efficiency at 36.1%
Revenue surging 141.6% year-over-year
Safe zone — low bankruptcy risk
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Trading at 17.0x book value
0.0% earnings growth
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : EMPG
The strongest argument for EMPG centers on Return on Equity, Operating Margin, Revenue Growth. Revenue growth of 141.6% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : EMPG
The primary concerns for EMPG are Price/Book, EPS Growth, Market Cap. A P/E of 192.9x leaves little room for execution misses.
Key Dynamics to Monitor
AZN profiles as a value stock while EMPG is a growth play — different risk/reward profiles.
EMPG is growing revenue faster at 141.6% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (64/100 vs 47/100), backed by strong 17.4% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Empro Group Inc. Ordinary shares
HEALTHCARE · MEDICAL DISTRIBUTION · USA
Empro Group Inc., through its subsidiary, sells healthcare and beauty products in Malaysia and internationally. The company is headquartered in Shah Alam, Malaysia.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?